Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 70
Updated:3/15/2019
Start Date:December 12, 2018
End Date:August 24, 2020
Contact:Daniel Snyder, PhD
Email:dsnyder@revance.com
Phone:510-742-3523

Use our guide to learn which trials are right for you!

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

This is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial
to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of
Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury. The study will be
conducted in the U.S.A. , approximately 128 adult subjects from approximately 30 study
centers will be randomly assigned (1:1:1:1) to one of four treatment groups. The study
consists of a 21-day screening period, a treatment visit and follow-up visits. The study is
expected to last approximately 2 years, and the duration of individual subject participation
will vary.

Subjects will be randomly assigned to DAXI for Injection high dose, DAXI for Injection medium
dose, DAXI for Injection low dose, or placebo group, respectively. Eligible subjects will
have ULS characterized by a primary aggregate posture

Inclusion Criteria:

- 18 to 70 years of age

- Written informed consent including authorization to release health information

- Focal upper limb spasticity (ULS) after a stroke (as defined by WHO criteria) or
traumatic brain injury (TBI), last stroke or TBI > 24 weeks prior to Screening

- ULS with the primary aggregate posture

- Moderate to severe ULS with a MAS score ≥ 2 at the elbow, wrist, and finger flexors

- Moderate to severe functional disability (Disability Assessment Score [DAS] score ≥2)
on the principal target of treatment

- Has sufficient cognitive and communication ability to be able to give informed consent

Exclusion Criteria:

- Upper limb spasticity attributable to an etiology other than stroke or TBI.

- Bilateral upper limb paresis or quadriplegia.

- Initiated in physiotherapy of the upper extremities ≤ 30 days prior to Screening or
planned to start physiotherapy of the upper extremities during the course of the
study.

- Previous or planned treatment of the spastic upper limb with phenol, alcohol
injection, or surgery

- Profound muscular atrophy or fixed contracture leading to marked limitation on range
of motion

- Prior treatment with intrathecal baclofen

- Any neuromuscular neurologic conditions (amyotrophic lateral sclerosis, Lambert-
Eaton, myasthenia gravis)
We found this trial at
8
sites
?
mi
from
Stamford, CT
Click here to add this to my saved trials
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
?
mi
from
Fairfield, CT
Click here to add this to my saved trials
Fountain Valley, California 92708
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Long Beach, California 90806
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
Overland Park, Kansas 66211
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Salem, North Carolina 27157
?
mi
from
Salem, NC
Click here to add this to my saved trials